Heparin and atherosclerosis: an investigative report on the treatment of atherosclerosis.

Both animal and clinical evidence of the special role of long-term low-dose heparin as a preventative of atherosclerosis is presented. Some of the many beneficial effects of heparin aside from its anticoagulant capability are mentioned. Concern about hemorrhage and osteoporosis which can occur when taken in the usual anticoagulant doses does not apply to long-term administration of low-dose heparin. Taken by the intrapulmonary route using an ultrasonic nebulizer weekly or fortnightly, heparin is safe and assures patient compliance. Further clinical trials are strongly indicated.